EUDA Health Holdings Limited (EUDAW) स्टॉक विश्लेषण

कंपनी का अवलोकन

EUDA Health Holdings Limited operates primarily in the healthcare sector, delivering non-invasive medical services across Singapore, Malaysia, and China through offerings such as bioenergy capsules, stem cell therapy, and CRISPR gene editing treatments. The company also diversifies its operations by providing property management services in addition to its core healthcare portfolio. Regarding its operational scale, the firm employs a workforce of 117 individuals to support its service delivery and administrative functions. While specific market capitalization and price-to-sales data are currently unavailable in the provided financial records, the annual revenue of $5.16 million indicates a mid-sized enterprise operating within the biotechnology and healthcare services landscape. This revenue figure, combined with the employee count, suggests a lean organizational structure that relies heavily on high-value service delivery rather than mass manufacturing or extensive infrastructure deployment.

वित्तीय स्वास्थ्य

The company reported a total revenue of $5.16 million over the trailing twelve months, yet recorded a net income loss of $-2,064,341 and an EBITDA of $-1,992,526. The substantial disparity between the positive revenue of $5.16 million and the significant negative net income reveals a cost structure where operating expenses, likely driven by research and development or service delivery costs, heavily outweigh gross profits. Free cash flow stands at $-3,350,164, indicating that the company is currently burning cash rather than generating liquidity from its operations, which limits its immediate financial flexibility and reliance on external capital. An analysis of the three key margins shows a gross margin of 22.4%, suggesting that for every dollar of revenue, roughly 22.4 cents remains after direct costs, while the operating margin of -37.0% and a profit margin of 5.2% highlight significant operational inefficiencies or high fixed cost burdens relative to sales. The balance sheet shows cash reserves of $176,584 against total debt of $2.28 million, creating a situation where liabilities significantly exceed liquid assets. Although the debt-to-equity ratio is not disclosed in the available data, the disparity between cash and debt implies a leveraged position that requires careful cash flow management. The current ratio of 0.23 indicates that current assets are less than 23% of current liabilities, signaling potential short-term liquidity challenges and an inability to meet immediate obligations without refinancing or asset sales. Furthermore, the return on assets is -63.9% and return on equity is unavailable, metrics that collectively suggest the management has not yet been effective in generating returns on the capital employed or shareholders' equity, reflecting the early-stage or loss-making nature of the business model.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio and forward P/E ratio are both unavailable (N/A), which prevents a direct comparison of expected earnings trajectories or historical profitability multiples. Similarly, the price-to-book ratio is recorded at -0.01, a negative figure that indicates the company's market capitalization is effectively below its book value or that the book equity is negative, a common characteristic for unprofitable biotech firms. The price-to-sales ratio and EV/EBITDA multiples are also not available in the current dataset, meaning alternative valuation metrics cannot be used to assess the premium or discount relative to peers. Regarding trading range, the 52-week high and low are both recorded at $0.03, meaning the stock has shown no price movement within the past year and is trading exactly at both the high and low boundaries. Consequently, the current price sits at 0% deviation from the 52-week high and low, reflecting a period of stagnation or extreme consolidation rather than active trading volume or volatility. The beta value is 0.16, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting the asset may be less sensitive to general market fluctuations but also potentially offering lower risk-adjusted returns. This low beta, combined with the lack of earnings data, suggests the stock price is driven more by sentiment or speculative factors than fundamental earnings performance.

Growth & Income

Revenue growth year-over-year stands at 60.2%, demonstrating a rapid expansion in top-line sales, whereas earnings growth is unavailable due to the company's negative net income position. The absence of positive earnings growth implies that while the company is successfully acquiring customers or increasing service volume, profitability has not yet scaled to match this revenue expansion. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio to shareholders, indicating that all available cash is retained to fund operations, research, or debt servicing rather than being returned to investors. This reinvestment strategy is typical for growth-stage companies in the biotechnology sector that prioritize capital allocation toward developing treatments like stem cell therapy over immediate shareholder payouts. The overall growth and income profile is characterized by high revenue expansion coupled with current losses and a lack of dividend income, positioning the asset as a high-risk, high-potential growth vehicle dependent on future profitability to sustain operations.